What's in Tasly Tianjin Biopharmaceutical Co., Ltd.'s pipeline?

Tasly Tianjin Biopharmaceutical Co., Ltd. has 3 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Tasly Tianjin Biopharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Asan Medical Center, Avexa, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tasly-tianjin-biopharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Tasly Tianjin Biopharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tasly Tianjin Biopharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
Asan Medical Center · 1 shared drug class
Avexa · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Dong-A ST Co., Ltd. · 1 shared drug class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tasly Tianjin Biopharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Tasly Tianjin Biopharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tasly-tianjin-biopharmaceutical-co-ltd. Accessed 2026-05-17.